Researchers have developed a new blood test that can identify cancer in the body as part of a National Health Service (NHS) ...

Terry Bradshaw was the golden-armed leader of the Pittsburgh Steelers dynasty, a two-time Super Bowl MVP, a four-time ...

A pivotal trial of an electronic artificial urinary sphincter could herald the future of treating incontinence.

Queensland researchers have discovered why potentially deadly cancers may be resistant to immunotherapy in a breakthrough ...

GlycoNex, Inc. (4168, hereinafter referred to as GNX), a clinical stage biotechnology company focused on the development of glycan-directed cancer immunotherapies, today announced the presentation of ...

Poster presentations highlight antitumor activity and safety of novel PSMA-targeted and ASCT2-targeted ADCs LAUSANNE, Switzerland /PRNewswire/ -- ADC Therapeutics ...

TAR-200 demonstrated a high disease-free survival and bladder preservation rates in BCG-unresponsive, high-risk ...

Cretostimogene grenadenorepvec is an investigational oncolytic immunotherapy that is being studied for the treatment of bladder cancer, particularly non-muscle invasive bladder cancer (NMIBC) that is ...

May is Bladder Cancer Awareness Month and at Frontiers in Oncology, we are dedicated to spotlighting the groundbreaking discoveries transforming the ...

Oncologists at AUA 2025 share promising data, including sasanlimab, cretostimogene grenadenorepvec, and TAR-200 in NMIBC.

The Food and Drug Administration (FDA) has approved Imfinzi ® (durvalumab), in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent Imfinzi as adjuvant ...